Co-Diagnostics – No More Debt and Cash on the Balance Sheet

NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Co-Diagnostics, Inc., (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, capped a volatile month of trading with some positive financial news. A recent sale of $3 million of preferred shares effectively eliminated the company’s debt by converting $2 million of debt to preferred stock; the sale also included $1 million of preferred shares for cash. The transaction was described by Co-Diagnostics CEO in the official announcement as beneficial to shareholders by accelerating the company’s growth strategy.

All preferred shares are convertible to common stock at a fixed price of $1.20/share. Debt elimination plus a warrantless capital infusion together add up to an improved balance sheet, and one that objectively presents a much healthier snapshot of the company’s financial state.

Remarks by Co-Diagnostics CEO Dwight Egan in the company’s press announcement included the belief that ”This exciting era of the Company’s expansion will continue as we build on our notable scientific, regulatory, and strategic milestones from 2018. The Company’s improved balance sheet also provides a strong foundation for continued momentum.”

Pricing the conversion at a premium to the previous day’s close of $1.11 does appear to reflect bullish confidence on behalf of all parties involved that the share price will follow the company’s continued progress in the key growth areas they have previously identified, notably: infectious disease testing, agrigenomics, liquid biopsy and NGS applications. This growth is expected to be made possible by the significant advantages of the company’s patented CoPrimer™ technology compared to other molecular diagnostics, and the adoption of that technology through the sale of diagnostic tests and technology license agreements.

About The Wall Street Club:

The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC writes about stocks in both free and paid content. WSC accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the Wall Street Club may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words ”anticipate,” ”intend,” ”estimate,” ”believe,” ”expect,” ”plans,” ”should,” ”potential,” ”forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Press Contact:

The Wall Street Club
www.wallstreetclub.com
press@wallstreetclub.com

SOURCE: Co-Diagnostics, Inc.

ReleaseID: 534006